Breaking News

SK Biopharmaceuticals, Eurofarma Enter Cenobamate Licensing Pact in Latin America

Eurofarma, a Brazilian pharmaceutical company, to develop and commercialize cenobamate in Latin America for the treatment of epilepsy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

SK Biopharmaceuticals, Co., Ltd., has entered into a licensing agreement for Eurofarma, a Brazilian pharmaceutical company, to develop and commercialize cenobamate in Latin America for the treatment of epilepsy. Cenobamate is approved and available in the U.S. and Europe for the treatment of partial-onset seizures in adults.   Under the terms of the agreement, SK Biopharmaceuticals has granted Eurofarma the exclusive rights to develop and commercialize cenobamate in Latin America. In return, S...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters